<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Efforts to reduce the burden of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD) associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> should include increased emphasis on preventing progression to <z:mp ids='MP_0002055'>diabetes</z:mp> in individuals with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent large-scale studies have shown that lifestyle intervention can reduce progression to <z:mp ids='MP_0002055'>diabetes</z:mp> by nearly 60% </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> is a risk factor for CHD in diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>Accumulation of evidence indicating significant reductions in CHD risk with <z:chebi fb="0" ids="35664">statin</z:chebi> treatment to lower <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>)-cholesterol has led to the recommendation that reduction of <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> be considered the highest priority in treating diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>; additional aims of treatment include raising <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>)-cholesterol and reducing <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>In a recent trial of <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> alone or combined with <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> in diabetic patients with combined <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e>, <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> 40 mg monotherapy produced marked beneficial changes in <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (-47%), <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (+6%) and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (-30%), with the combination of lower-dose <z:chebi fb="0" ids="38545">rosuvastatin</z:chebi> (10 mg) and <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> producing a significantly greater <z:chebi fb="0" ids="17855">triglyceride</z:chebi> reduction (-47%) and comparable changes in other <z:chebi fb="23" ids="18059">lipid</z:chebi> measures </plain></SENT>
<SENT sid="5" pm="."><plain>Combination therapies for <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> may be the key to optimizing CHD risk reduction in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>